A Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability,Efficacy and Pharmacokinetics of YH001 in Subjects With Advanced Solid Tumors
Latest Information Update: 15 Dec 2022
At a glance
- Drugs YH 001 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eucure Biopharma
Most Recent Events
- 09 Dec 2022 Status changed from recruiting to completed.
- 26 Jan 2021 According to an Eucure Biopharma media release, first patient has been enrolled in the trial.
- 20 Jan 2021 Status changed from not yet recruiting to recruiting.